Effects of Semaglutide on Body Mass Index (BMI) and Cardiometabolic Profile in Adolescents With Variants in Monogenic Obesity‐Related Genes
Authors' conclusion
Semaglutide was associated with significant reductions in BMI and cardiometabolic markers in adolescents (majority White) with dominant or known risk variants for monogenic obesity.
Study context
- Population
- Adolescents with severe obesity who underwent multigene panel testing and were treated with semaglutide; mean age 15 ± 1.9 years, BMI % of 95th percentile 158 ± 29, 70% White
- Participants
- 27 adolescents
- Exposure
- Semaglutide treatment across genetic variant groups
- Dominant or Known Risk Variantsn = 7
- Carriers of Rare Variants in Recessive Genesn = 10
- Negative or Unmatched Genetic Findingsn = 10
- Outcome
- BMI change
- Follow-up
- Mean 10 ± 4.7 months of semaglutide
Main finding
As reported in the abstract
- All groups showed reductions in BMI, not different between the groups
Observational data: associations, not effects.
Further findings
- BMI % of 95th percentile change (Dominant or Known Risk Variants)
- −17 · IQR −26–-10
- BMI % of 95th percentile change (Dominant or Known Risk Variants) — Significant decrease, p = 0.022
- −17
- BMI change (Dominant or Known Risk Variants)
- −9.4% · ± 7%
- BMI change (Dominant or Known Risk Variants) — Significant decrease, p = 0.035
- −9.4%
Cardiometabolic markers (Dominant or Known Risk Variants)
- Median non-HDL cholesterol change
- −16 mg/dL
- Total cholesterol change
- −15 mg/dL
- HbA1c change
- −0.3%
- Significant improvements
- P = 0.036
Original publication
Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents With Variants in Monogenic Obesity‐Related Genes. Pediatr Obes. Published 10 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →